Lucida Medical, the University of Cambridge, and Hampshire Hospitals National Health Service (NHS) Foundation Trust have been awarded funding by Innovate UK and the Office for Life Sciences to extend the Pi software platform to multiple clinical indications.
The £1 million program, certified to support cancer diagnosis, will allow for the platform to be used throughout a patient’s prostate cancer care journey with prostate cancer. Pi uses AI to combine insights from MRI and clinical tests.
The latest collaborative project will extend the Pi platform to further support active surveillance of patients living with prostate cancer. Hampshire Hospitals NHS Foundation Trust will lead the development of a new dataset of patients on active surveillance. Lucida Medical will use this to train new AI algorithms and develop additional workflows to extend the Pi platform. The University of Cambridge will then evaluate the platform with data from prostate cancer patients dating back over the last 10 years.
Lucida Medical will showcase Pi at ECR 2024, which begins in Vienna on 28 February.
